The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris
The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Previous mega trials have demonstrated that lipid-lowering therapy with HMG-CoA reductase inhibitors in individuals with high risk of cardiovascular disease reduces the incidence of coronary heart disease. NCEP ATP-III has suggested the advantage of more intensive lipid lowering therapy with a goal of reducing LDL-C below 70 mg/dL for such patients categorized as very high risk. In Japan, Japan Atherosclerosis Society (JAS) Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases 2002 have recommended that an LDL-C goal for patients with coronary heart disease (CHD) should be below 100 mg/dL. However, there is no satisfactory evidence whether the investigators need to lower LDL-C level less than the 70mg/dL or not in Japanese population.
Recently, research on diagnosis of coronary plaque has shown significant advances. The REVERSAL study in patients with a history of CHD, by diagnosis with intravascular ultrasound (IVUS), suggested that intensive lipid lowering therapy with atorvastatin (80 mg/day) was associated with no growth of plaque (-0.4% compared to baseline), whereas therapy with pravastatin (40 mg/day) showed a slight increase (2.7%) in plaque volume over 18 months in Western population.
MEGA study has shown that lipid lowering therapy with pravastatin (10-20 mg/day) was associated with a 33% reduction in coronary heart disease incidence as the primary prevention in Japanese patients. However, the effect of lipid lowering therapy in secondary prevention of cardiovascular events is unknown.
Relative plaque regression rate between intensive and moderate lipid lowering therapy would clarify the ideal level of target LDL-C in Japanese population. Furthermore, the different effect on coronary plaque between pravastatin and rosuvastatin which have different LDL-C lowering effect and different affinity to arterial tissue would determine the superior lipid lowering regimen to affect coronary plaque volume.
Therefore, the aim of the present study is to evaluate whether there would be lipid lowering therapy differences in terms of the composition of coronary artery plaques in patients with stable angina pectoris (SAP) using integrated backscatter intravascular ultrasound (IB-IVUS) and optical coherence tomography (OCT).
Type d'étude
Type d'étude
Inscription (Anticipé)
Inscription
Phase
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Kenichiro Saka
- Numéro de téléphone: 81-45-261-5656
- E-mail: Ken_saka@yokohama-cu.ac.jp
Lieux d'étude
-
-
-
Yokohama, Japon
- Recrutement
- Yokohama City University Medical Center
-
Contact:
- Kenichiro Saka
- Numéro de téléphone: 81-45-261-5656
- E-mail: Ken_saka@yokohama-cu.ac.jp
-
Chercheur principal:
- Kenichiro Saka
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients who have been diagnosed as stable angina pectoris, and successful percutaneous coronary intervention (PCI) were performed with intravascular ultrasound (IVUS) and optical coherence tomography (OCT) guidance.
- Patients having coronary plaques (≧ 500 µm in thickness or % plaque of 20% or more at ≧ 5 mm distal or proximal to the previously treated area in the same branch of coronary artery.
Patients with dyslipidemia as defined by any of the following criteria:
- TC ≧ 220 mg/dL
- LDL-C ≧ 140 mg/dL
- Cholesterol-lowering treatment is allowed according to the investigator's judgment when LDL-C ≧ 100 mg/dL or TC ≧ 180mg/dL.
- Patients who are under cholesterol-lowering treatment and LDL-C ≦ 120 mg/dL
- Patients 20 years or older at the time of their consent.
- Patients with written consent by their own volition after being provided sufficient explanation for their participation in this clinical trial.
Exclusion Criteria:
- Patients with bypass graft or in-stent restenosis at the site of PCI.
- Patients who received PCI in the past on the lesion where the evaluation of coronary plaque volume is planned.
- Patients who had plaques in a non-culprit site and might receive PCI during the treatment period.
- Patients receiving lipid-lowering drugs (fibrates, probucol, nicotinic acid, cholestyramine or cholesterol absorption inhibitors).
- Patients with familial hypercholesterolemia.
- Patients with cardiogenic shock.
- Patients receiving cyclosporine.
- Patients with any allergy to pravastatin and rosuvastatin.
- Patients with hepatobiliary disorders.
- Pregnant women, women suspected of being pregnant, or lactating women.
- Patients with renal disorders (Cr≧2.0mg/dL) or undergoing dialysis.
- Patients who are ineligible in the opinion of the investigator.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Comparateur actif: 1:pravastatin, 2:rosuvastatin
|
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
the percent change in fibrous cap thickness by optical coherence tomography
Délai: 9-11 months
|
the percent change in fibrous cap thickness by optical coherence tomography
|
9-11 months
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
the percent change and the absolute change from baseline in coronary plaque volume and IB signal obtained by IB-IVUS
Délai: 9-11 months
|
the percent change and the absolute change from baseline in coronary plaque volume, the percent change in integrated backscatter signal obtained by integrated backscatter IVUS
|
9-11 months
|
|
the absolute change from baseline in number of TCFA and plaque rupture, and in neointima thickness on stent struts by OCT
Délai: 9-11 months
|
the absolute change from baseline in number of TCFA, plaque rupture, thrombus, calcification, and in neointima thickness on stent struts by optical coherence tomography
|
9-11 months
|
|
the percent change and the absolute change from baseline in total cholesterol and LDL cholesterol
Délai: 9-11 months
|
the percent change and the absolute change from baseline in total cholesterol and low-density lipoprotein cholesterol
|
9-11 months
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Chaise d'étude: Kiyoshi Hibi, Yokohama City University Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement primaire
Achèvement de l'étude (Anticipé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Dyslipidémie
- Maladies cardiovasculaires
- Maladie de l'artère coronaire
- Actions pharmacologiques
- Rosuvastatine
- Artériosclérose
- Maladies cardiaques
- Utilisations thérapeutiques
- Antimétabolites
- Maladie coronarienne
- Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase
- Mécanismes moléculaires de l'action pharmacologique
- Angine de poitrine stable
- Maladies artérielles occlusives
- Agents anticholestérolémiants
- Agents antilipémiques
- Vascular Diseases Pravastatin
Termes MeSH pertinents supplémentaires
- Ischémie myocardique
- Maladies cardiaques
- Maladies cardiovasculaires
- Maladies vasculaires
- Maladies métaboliques
- Artériosclérose
- Maladies artérielles occlusives
- La douleur
- Manifestations neurologiques
- Troubles du métabolisme lipidique
- Hyperlipidémies
- Dyslipidémies
- Douleur thoracique
- Maladie de l'artère coronaire
- Maladie coronarienne
- Hypercholestérolémie
- Angine de poitrine
- Angine stable
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Antimétabolites
- Agents anticholestérolémiants
- Agents hypolipidémiants
- Agents de régulation des lipides
- Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase
- Rosuvastatine calcique
- Pravastatine
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- YCUMC20110324
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .